Obseva Sahares (NASDAQ:OBSV) Can’t Be Less Risky. Short Interest Decreased

October 11, 2018 - By Louis Casey

The stock of Obseva Sahares (NASDAQ:OBSV) registered a decrease of 45.41% in short interest. OBSV’s total short interest was 36,900 shares in October as published by FINRA. Its down 45.41% from 67,600 shares, reported previously. With 38,200 shares average volume, it will take short sellers 1 days to cover their OBSV’s short positions. The short interest to Obseva Sahares’s float is 0.18%.

The stock decreased 2.96% or $0.48 during the last trading session, reaching $15.75. About 5,997 shares traded. ObsEva SA (NASDAQ:OBSV) has risen 105.86% since October 11, 2017 and is uptrending. It has outperformed by 90.24% the S&P500.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company has market cap of $715.89 million. The firm intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It currently has negative earnings. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy.

More notable recent ObsEva SA (NASDAQ:OBSV) news were published by: Streetinsider.com which released: “ObsEva SA (OBSV) Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at ASRM” on October 09, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on September 13, 2018, Seekingalpha.com published: “ObsEva’s Nolasiban increased live birth rate in late-stage study” on October 03, 2018. More interesting news about ObsEva SA (NASDAQ:OBSV) were released by: Seekingalpha.com and their article: “ObsEva up 13%” published on September 17, 2018 as well as Nasdaq.com‘s news article titled: “ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM …” with publication date: October 05, 2018.

ObsEva SA (NASDAQ:OBSV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>